Introduction: Gastric cancer (GC) remains one of the most lethal neoplasms, representing a significant public health challenge despite its global decline. Objectives: To investigate the association between family history and gastric cancer in order to propose prevention and control recommendations for public health. Methods: This descriptive and retrospective study examined the association between family history and the risk of GC in 1,638 patients diagnosed with invasive gastric adenocarcinoma, treated between 2018 and 2024 at João de Barros Barreto Hospital (HUJBB) and Ophir Loyola Hospital (HOL), in Belém, Pará, Brazil. Electronic medical records were analyzed, including data on sex, age, geographic origin, ICD classification, tumor location, histological subtypes, family history of GC (detailed by degree of kinship), presence of other cancers in the family, and patient mortality. The study was approved by the Research Ethics Committee (CEP) of the Oncology Research Center at the Federal University of Pará, under protocol number 70774823.0.0000.5634. Results: A family history of GC was found in 12.3% of patients at HUJBB and 9.75% at HOL, indicating a statistically significant association (p < 0.05). Patients under 40 years of age showed a higher frequency of family history (36.3%) compared to 11.6% in the 41–60 age group and 6.6% in those over 60 years (p < 0.01). Women showed a slightly higher likelihood of GC associated with family history. Most cases involved first- and second-degree relatives, with a predominance of tumors located in the antrum. Conclusion: These findings highlight regional characteristics, such as the high prevalence among young patients in the Amazon region, and reinforce the need for public policies that promote upper gastrointestinal endoscopy screening among first- and second-degree relatives of patients with GC, especially younger individuals, to enable early detection and reduce mortality.
It is with great enthusiasm that we present the Annals of the Oncology International Symposium 2025, an event that continues to solidify its significance in the oncology landscape of northern Brazil. Held in Belém, Pará, Oncology 2025 centered around the theme "The cancer control challenge: better knowing it to best facing it," dedicating itself to exploring the latest frontiers in cancer treatment and prevention.
This year, the symposium provided a deep dive into the essential role of knowledge in the fight against cancer, presenting new perspectives and scientific advancements across various areas of oncology. Renowned global experts gathered to share their most recent research and innovative approaches, offering participants a comprehensive view of the challenges faced by healthcare professionals and patients worldwide.
Presentations and discussions during the event focused on critical topics such as the use of new technologies, advancements in personalized therapies, and more effective prevention strategies. Additionally, particular attention was given to the unique challenges faced by the Amazon region, with efforts aimed at developing region-specific solutions to meet local needs.
Beyond being a high-caliber academic event, Oncology 2025 stood out as a moment for integration and professional networking, with the warm hospitality of the city of Belém offering participants a unique experience. This event became a platform for exchanging ideas, where science, culture, and humanity came together in pursuit of a common goal: to improve cancer control both in Brazil and globally.
This collection of abstracts and articles presented during the event reflects the ongoing dedication to research and the development of innovative solutions, highlighting the importance of collaboration and shared knowledge in the fight against cancer.
General Submission Guidelines:
The presenting author, who does not have to be the first author, must be registered for Oncology 2025.
Each abstract may have up to 10 authors, including the main author and co-authors.
Only original, unpublished work will be accepted.
Submissions must be related to oncology. However, project descriptions, work proposals, experience reports, and literature reviews will not be considered.
Clinical case reports are allowed, provided the abstract addresses scientific questions, details clinical observations, and includes primary scientific data.
The abstract must be written in English, but presentations may be given in Portuguese.
Abstracts must be between 300 and 500 words.
Comissão Organizadora
Comissão Científica
See Annals of Oncology 2023 at:
https://www.even3.com.br/anais/oncology-2023-international-symposium/
Complete tool for submission, evaluation and publication of proceedings for scientific events.
